Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)

INTRODUCTION: Given an increasing use of dipeptidyl peptidase-4 (DPP-4) inhibitors to treat patients with type 2 diabetes mellitus in the real-world setting, we conducted a prospective observational study (Japan-based Clinical Research Network for Diabetes Registry: J-BRAND Registry) to elucidate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueki, Kohjiro, Tanizawa, Yukio, Nakamura, Jiro, Yamada, Yuichiro, Inagaki, Nobuya, Watada, Hirotaka, Shimomura, Iichiro, Nishimura, Rimei, Miyoshi, Hideaki, Abiko, Atsuko, Katagiri, Hideki, Hayashi, Michio, Shimada, Akira, Naruse, Keiko, Fujimoto, Shimpei, Fujiwara, Masazumi, Shikata, Kenichi, Okada, Yosuke, Araki, Eiichi, Yamazaki, Tsutomu, Kadowaki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical care/Education/Nutrition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812112/
https://www.ncbi.nlm.nih.gov/pubmed/33441417
http://dx.doi.org/10.1136/bmjdrc-2020-001787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812112/
https://www.ncbi.nlm.nih.gov/pubmed/33441417
http://dx.doi.org/10.1136/bmjdrc-2020-001787

Ejemplares similares